From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
PHA-543613 structure.png
CAS Number
PubChem CID
ECHA InfoCard100.189.975 Edit this at Wikidata
Chemical and physical data
Molar mass271.314 g·mol−1
3D model (JSmol)

PHA-543,613 is a drug that acts as a potent and selective agonist for the α7 subtype of neural nicotinic acetylcholine receptors, with a high level of brain penetration and good oral bioavailability. It is under development as a possible treatment for cognitive deficits in schizophrenia.[1]


  1. ^ Wishka, D.; Walker, D.; Yates, K.; Reitz, S.; Jia, S.; Myers, J.; Olson, K.; Jacobsen, E.; Wolfe, M.; Groppi, V.; Hanchar, A. J.; Thornburgh, B. A.; Cortes-Burgos, L. A.; Wong, E. H. F.; Staton, B. A.; Raub, T. J.; Higdon, N. R.; Wall, T. M.; Hurst, R. S.; Walters, R. R.; Hoffmann, W. E.; Hajos, M.; Franklin, S.; Carey, G.; Gold, L. H.; Cook, K. K.; Sands, S. B.; Zhao, S. X.; Soglia, J. R.; Kalgutkar, A. S. (2006). "Discovery of N-(3R)-1-azabicyclo2.2.2oct-3-ylfuro2,3-cpyridine-5-carboxamide, an agonist of the alpha7 nicotinic acetylcholine receptor, for the potential treatment of cognitive deficits in schizophrenia: synthesis and structure--activity relationship". Journal of Medicinal Chemistry. 49 (14): 4425–4436. doi:10.1021/jm0602413. PMID 16821801.